Related Articles
Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy
Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model
Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment
Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin
Bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer